From the 10-Q but conveniently not announced on the investor call... "During the three months ended June 28, 2019, the Company recognized a full impairment on its in-process research and development ("IPR&D") asset related to stannsoporfin of $113.5 million as the Company will no longer pursue this development product." Great idea to spend $80 million on Infacare 2 years ago...great ROI... MNK business strategy...overpay and over borrow for assets no one else wants, destroy them in the marketplace or in the clinics, then take massive write downs in the future. Brilliant!
...I do not think they have publicly announced that they have failed miserably at completing trials that gain successful market approval...nor have they admitted that they over pay, over leverage debt to buy products no one else wants or will pay for, inflate earnings per share through manipulating their costs and to boost their bonuses...This team does not admit they are the laughing stock of the industry. However, thanks for monitoring the comments and trying to defend these fraudsters...
The original post was about the purchase. Which they addressed multiple times. The other stuff you brought up had nothing to do with the original post. You must be the guy they keep talking about with piss stains on his pants.
they just sold the rights to the name Sonorant to Hugh’s brother for 19 million. He will rent it back to use for 4 million a year once the company goes active however if we go bankrupt first his brother gets a bonus of 25 million.
